

***Fiscal Year 2022 RCRP Research Program (RCRP)***  
***Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Concept Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-RCRP-CA</a></p>	<p>Investigators at or above the level of postdoctoral fellow.</p>	<ul style="list-style-type: none"> <li>• Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers. Proof-of-concept is the anticipated outcome.</li> <li>• Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers. Proof-of-concept is the anticipated outcome.</li> <li>• Submission must address at least one of the FY22 Focus Areas.</li> <li>• Preliminary data are not required.</li> <li>• Clinical trials are not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$100,000</b> for direct costs (plus indirect costs).</li> <li>• The maximum period of performance is <b>1</b> year.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b>            July 18, 2022            5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b>            August 29, 2022            11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-RCRP-IDA</a></p>	<p>Investigators at or above the level of Assistant Professor.</p>	<ul style="list-style-type: none"> <li>• Supports innovative, high-risk/high-reward research with the potential to yield impactful data in the rare cancer field.</li> <li>• <i>Preliminary data with disease-specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required.</i></li> <li>• Submission must address at least one of the FY22 Focus Areas of Biology and Etiology, Research Model, and/or Therapy.</li> <li>• Clinical trials are not allowed.</li> <li>• <i>Pre-application submission is required; application submission is by invitation only.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$350,000</b> for direct costs (plus indirect costs).</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 22, 2022 5:00 p.m. ET</p> <p><b>Application:</b> October 6, 2022 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Resource and Community Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-RCRP-RCDA</a></p>	<p>Investigators at or above the level of Assistant Professor.</p>	<ul style="list-style-type: none"> <li>• Emphasis on research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians, and other members of the rare cancers community.</li> <li>• Supports platform development or infrastructure that can be applied to multiple rare cancers.</li> <li>• Preliminary data are not required but may be included (translational research and clinical studies may be included).</li> <li>• Submission must address the FY22 Platform Development Focus Area.</li> <li>• Clinical trials are not allowed.</li> <li>• <i>Pre-application submission is required; application submission is by invitation only.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$600,000</b> for direct costs (plus indirect costs).</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 22, 2022 5:00 p.m. ET</p> <p><b>Application:</b> October 6, 2022 11:59 p.m. ET</p>